Cencora (COR) Scheduled to Post Quarterly Earnings on Wednesday

Cencora (NYSE:COR) will post its quarterly earnings results before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of $3.65 per share for the quarter. Cencora has set its FY 2024 guidance at 13.250-13.500 EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, January 31st. The company reported $3.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.86 by $0.42. The business had revenue of $72.25 billion for the quarter, compared to analyst estimates of $68.81 billion. Cencora had a net margin of 0.69% and a return on equity of 323.23%. During the same quarter last year, the business earned $2.71 earnings per share. On average, analysts expect Cencora to post $13 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Cencora Stock Down 0.4 %

COR opened at $239.93 on Tuesday. The company has a market cap of $47.86 billion, a PE ratio of 26.14, a price-to-earnings-growth ratio of 1.84 and a beta of 0.45. Cencora has a twelve month low of $163.37 and a twelve month high of $246.75. The company has a 50-day moving average price of $238.72 and a 200 day moving average price of $218.20. The company has a quick ratio of 0.52, a current ratio of 0.88 and a debt-to-equity ratio of 3.94.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 26th. Shareholders of record on Friday, February 9th were paid a dividend of $0.51 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.24. This represents a $2.04 annualized dividend and a yield of 0.85%. The ex-dividend date of this dividend was Thursday, February 8th. Cencora’s payout ratio is 22.22%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on COR. Barclays initiated coverage on Cencora in a research note on Wednesday, January 3rd. They issued an “overweight” rating and a $242.00 price target on the stock. StockNews.com raised shares of Cencora from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 1st. SVB Leerink initiated coverage on shares of Cencora in a research note on Monday, February 26th. They issued an “outperform” rating and a $261.00 price target on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of Cencora in a research note on Monday, February 26th. Finally, Mizuho increased their price objective on shares of Cencora from $192.00 to $224.00 and gave the company a “neutral” rating in a report on Monday, February 5th. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $218.22.

Insider Buying and Selling at Cencora

In other news, EVP Elizabeth S. Campbell sold 6,977 shares of Cencora stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $238.12, for a total transaction of $1,661,363.24. Following the sale, the executive vice president now owns 8,246 shares of the company’s stock, valued at approximately $1,963,537.52. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, EVP Elizabeth S. Campbell sold 6,977 shares of the firm’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $238.12, for a total transaction of $1,661,363.24. Following the completion of the sale, the executive vice president now directly owns 8,246 shares of the company’s stock, valued at approximately $1,963,537.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Steven H. Collis sold 10,754 shares of the business’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $237.48, for a total transaction of $2,553,859.92. Following the completion of the sale, the chief executive officer now owns 285,088 shares in the company, valued at $67,702,698.24. The disclosure for this sale can be found here. Insiders have sold 4,288,790 shares of company stock worth $1,009,641,379 in the last ninety days. 15.80% of the stock is owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.